🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
Organization UNIVERSITY OF MIAMI SCHOOL OF MEDICINELocation CORAL GABLES, UNITED STATESPosted 7 Mar 2023Deadline 28 Feb 2026 ⚠️
NIHUS FederalResearch GrantFY2025AccountingAddressAdoptive TransferAntineoplastic VaccineAttenuatedAutocrine SystemsBehaviorBeta Proprotein Interleukin 1Blood SerumBlood VesselsBlood granulocytic cellBlood monocyteBone MarrowBone Marrow Reticuloendothelial SystemBrain CancerCAR T cell therapyCAR T therapyCD134Cancer VaccinesCancersCell BodyCell Growth in NumberCell LineageCell MultiplicationCell ProliferationCellsCellular ProliferationCheckpoint inhibitorChimeraChimera organismCirculationClinical TrialsComplementComplement ProteinsDevelopmentDifferences between sexesDiffers between sexesDiseaseDisease OutcomeDisorderDrugsExpression SignatureFemaleFoundationsFrequenciesGametesGene Expression ProfileGeneralized GrowthGenerationsGerm CellsGerm-Line CellsGlioblastomaGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGranular LeukocytesGranulocytic cellGrowthIL-1 betaIL-1 βIL-1-bIL-1βIL1-BetaIL1-βIL1B ProteinIL1F2IL1βImmune Cell ActivationImmune EvasionImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunityImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyImpairmentIn VitroIncidenceIndividualInfiltrationInterleukin 1betaInterleukin-1 betaInterleukin-1βInterventionKnock-outKnockoutLaboratoriesLeftLineage TracingMalignantMalignant - descriptorMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMarrow monocyteMediatingMediatorMedicationMiceMice MammalsMurineMusMyeloid-derived suppressor cellsNeoplasm VaccinesNetwork AnalysisOX40OncogenesisOncolytic virusesPD-1 antibodyPD1 antibodyPathogenesisPathway AnalysisPathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPeripheralPharmaceutical PreparationsPhasePlayPopulation HeterogeneityPre-Clinical ModelPreclinical ModelsPredispositionPreinterleukin 1 BetaPrimary Brain NeoplasmsPrimary Brain TumorsProductionPrognosisReceptor ProteinRegulationReportingReproductive CellsResearchRoleSerumSex CellSex DifferencesSexual differencesSusceptibilityT-Cell ActivationT-Lymphocyte and NK-CellT-Lymphocyte and Natural Killer CellTestingTherapeuticTissue GrowthTumor CellTumor ImmunityTumor VaccinesTumor-associated macrophagesVariantVariationaCTLA-4aCTLA-4 antibodiesaCTLA4aPD-1aPD1activate T cellsantagonismantagonistanti programmed cell death 1anti-CTLA-4anti-CTLA-4 antibodiesanti-CTLA4anti-CTLA4 antibodiesanti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor immune responseanti-tumor immunityanti-tumor vaccineantiPD-1antitumor immunityattenuateattenuatesautocrinebiological sex as a modifiercancer immunitycancer microenvironmentcancer progenitorcancer progenitor cellscancer progressioncancer stem cellcancer stem like cellcell lineage analysiscell lineage mappingcell lineage tracingcell lineage trackingcellular lineage mappingcellular lineage trackingchemotherapychimeraschimeric antigen receptor (CAR) T cell therapychimeric antigen receptor T cell therapychimeric antigen receptor T therapyclinical efficacyclinical relevanceclinically relevantcomparing females and malescomparing women and mencomplement systemcomplementationdensitydetermine efficacydevelopmentaldiverse populationsdrug candidatedrug repositioningdrug repurposingdrug/agentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentsfemale patientsfemales compared to malesfemales compared with malesfemales versus malesfemales vs. malesfludarabinegene expression patterngene expression signaturegene signaturesgenetic signatureglioblastoma multiformeglobal gene expressionglobal transcription profilegranulocyteheterogeneous populationhost responseimmune activationimmune check pointimmune check point inhibitorimmune checkpointimmune drugsimmune evasiveimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunologic therapeuticsimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive myeloid cellsimmunosuppressive responseimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimprovedin vitro activityin vivoinhibitorinitial cellinsightmalemalignancymalignant progenitormalignant stem cellmonocytemyeloid suppressor cellsmyeloid-derived suppressive cellsneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnoveloncogenic progenitoroncogenic stem cellsontogenypathwaypatient oriented outcomespatients being femalepatients being womenpatients who are femalepharmacologicpolarized cellpopulation diversityprogenitor cell regenerationprogenitor cell self renewalprogenitor like cancer cellprogenitor regenerationprogenitor self renewalprogramsreceptorrepurposing agentrepurposing medicationresistance to therapyresistant to therapyresponseresponse to therapyresponse to treatmentsexsex as a biological factorsex as a biological measuresex as a biological risk factorsex as a biological variablesex as a biological variancesex as a biologically significant variablesex as a fundamental variablesex based differencessex-dependent differencessex-related differencessex-specific differencessexual cellsocial rolespongioblastoma multiformestandard of carestem and progenitor cell regenerationstem and progenitor cell self renewalstem cell regenerationstem cell self renewalstem like cancer cellsuccesssuppressive myeloid cellstherapeutic outcometherapeutic resistancetherapeutic responsetherapeutic targettherapy outcometherapy resistanttherapy responsetranscriptional profiletranscriptional signaturetranscriptometreatment resistancetreatment responsetreatment responsivenesstumortumor growthtumor immune microenvironmenttumor microenvironmenttumor progressiontumor-immune system interactionstumorigenesisvaccine for cancervascularwomen compared to menwomen compared with menwomen patientswomen versus menwomen vs. menα-CTLA-4α-CTLA4αCTLA-4αCTLA4αPD-1αPD1♀♂
Applications closed.
Description preview
PROJECT SUMMARY: Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median
survival of up to 20 months. Males have a 1.6-fold higher incidence of GBM compared to females and worse
disease outcome. Standard-of-care treatment and immunotherapies, which are currently in clinical trials, have
had limited success improving…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click